for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MorphoSys AG

MORG.DE

Latest Trade

116.90EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

79.70

 - 

146.30

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
116.90
Open
--
Volume
--
3M AVG Volume
3.65
Today's High
--
Today's Low
--
52 Week High
146.30
52 Week Low
79.70
Shares Out (MIL)
31.71
Market Cap (MIL)
3,739.08
Forward P/E
--
Dividend (Yield %)
--

Next Event

Full Year 2019 Morphosys AG Earnings Release

Latest Developments

More

Morphosys And Incyte Sign Collaboration And License Agreement For Tafasitamab

Morphosys To Submit Biologics License Application For Tafasitamab To FDA

Morphosys Says Co's CSO Markus Enzelberger Has Decided To Step Down

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MorphoSys AG

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Contact Info

Semmelweisstr. 7

+49.89.899270

https://www.morphosys.de/

Executive Leadership

Marc Cluzel

Independent Chairman of the Supervisory Board

Jean-Paul Kress

Chief Executive Officer

Frank Morich

Independent Vice Chairman of the Supervisory Board

Jens Holstein

Chief Financial Officer, Member of the Management Board

David Trexler

President - MorphoSys US Inc

Key Stats

2.00 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

-2.270

2017

-2.410

2018

-1.792

2019(E)

-3.089
Price To Earnings (TTM)
--
Price To Sales (TTM)
52.54
Price To Book (MRQ)
8.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.78
LT Debt To Equity (MRQ)
9.18
Return on Investment (TTM)
-18.72
Return on Equity (TTM)
-17.15

Latest News

Latest News

Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine

German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.

Chief scientist quits at Germany's Morphosys ahead of product launch

Morphosys' <MORG.DE> chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch.

Morphosys to boost size of tafasitamab drug trial on encouraging interim data

German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug against a common type of blood cancer, following an encouraging interim data readout.

Morphosys shares fall after dermatitis treatment flops

German biotech company Morphosys halted development of an experimental atopic dermatitis treatment that analysts had pinned hopes of blockbuster sales potential on, sending its shares down as much as 6.8% on Tuesday.

BRIEF-Morphosys Announces End Of Clinical Development Program Of MOR106 In Atopic Dermatitis

* ANNOUNCED END OF CLINICAL DEVELOPMENT PROGRAM OF MOR106 IN ATOPIC DERMATITIS

CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance

* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

German biotech group Morphosys seeks European partner for debut drug

German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Morphosys AG Files For U.S. IPO Of Up To $150 Mln

* MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING

BRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​

* SAYS FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING

BRIEF-Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018

* REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up